

George D Demetri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2416128/publications.pdf>

Version: 2024-02-01

90
papers

22,244
citations

76326

40
h-index

62596

80
g-index

91
all docs

91
docs citations

91
times ranked

18939
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. <i>New England Journal of Medicine</i> , 2002, 347, 472-480.	27.0	4,018
2	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. <i>Lancet, The</i> , 2006, 368, 1329-1338.	13.7	2,349
3	Efficacy of Larotrectinib in <i>TRK</i> -Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018, 378, 731-739.	27.0	2,036
4	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2012, 379, 1879-1886.	13.7	1,752
5	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013, 381, 295-302.	13.7	1,144
6	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology, The</i> , 2020, 21, 271-282.	10.7	1,034
7	NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-1-S-41.	4.9	1,004
8	Crizotinib in <i>ALK</i> -Rearranged Inflammatory Myofibroblastic Tumor. <i>New England Journal of Medicine</i> , 2010, 363, 1727-1733.	27.0	769
9	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017, 171, 950-965.e28.	28.9	738
10	Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2008, 26, 5352-5359.	1.6	693
11	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 786-793.	1.6	647
12	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. <i>Oncogene</i> , 2001, 20, 5054-5058.	5.9	643
13	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 1629-1637.	13.7	610
14	Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules. <i>Journal of Clinical Oncology</i> , 2009, 27, 4188-4196.	1.6	472
15	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncology, The</i> , 2007, 8, 595-602.	10.7	416
16	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. <i>Immunity</i> , 2017, 46, 197-204.	14.3	400
17	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1563-1570.	1.6	252
18	SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. <i>Nature Genetics</i> , 2017, 49, 1613-1623.	21.4	207

#	ARTICLE	IF	CITATIONS
19	Long-Term Outcomes After Function-Sparing Surgery Without Radiotherapy for Soft Tissue Sarcoma of the Extremities and Trunk. <i>Journal of Clinical Oncology</i> , 1999, 17, 3252-3259.	1.6	194
20	Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. <i>Nature</i> , 2019, 575, 229-233.	27.8	164
21	The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. <i>Nature Medicine</i> , 2020, 26, 181-187.	30.7	158
22	Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 871-879.	7.0	150
23	Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor. <i>Annals of Surgery</i> , 2013, 258, 422-429.	4.2	150
24	Dystrophin is a tumor suppressor in human cancers with myogenic programs. <i>Nature Genetics</i> , 2014, 46, 601-606.	21.4	142
25	Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure. <i>Clinical Cancer Research</i> , 2009, 15, 5902-5909.	7.0	133
26	Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. <i>Clinical Cancer Research</i> , 2012, 18, 3170-3179.	7.0	116
27	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2019, 120, 612-620.	6.4	109
28	Antiproliferative Effects of CDK4/6 Inhibition in <i>CDK4</i> -Amplified Human Liposarcoma <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2184-2193.	4.1	102
29	Cardio-Oncology. <i>Circulation</i> , 2015, 132, 2248-2258.	1.6	99
30	Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 550-560.	10.7	96
31	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	4.1	96
32	Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. <i>Cancer</i> , 2014, 120, 738-743.	4.1	84
33	Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. <i>European Journal of Cancer</i> , 2014, 50, 2162-2170.	2.8	82
34	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <i>NTRK</i> Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	7.0	74
35	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results. <i>JAMA Oncology</i> , 2017, 3, 944.	7.1	73
36	Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. <i>Oncotarget</i> , 2016, 7, 16581-16592.	1.8	57

#	ARTICLE	IF	CITATIONS
37	Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. <i>Hematology/Oncology Clinics of North America</i> , 2002, 16, 1115-1124.	2.2	56
38	Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 531-540.	10.7	56
39	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. <i>Nature Communications</i> , 2017, 8, 14674.	12.8	53
40	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. <i>Gynecologic Oncology</i> , 2017, 146, 531-537.	1.4	51
41	Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>Cancer</i> , 2019, 125, 2610-2620.	4.1	47
42	International expert opinion on patient-tailored management of soft tissue sarcomas. <i>European Journal of Cancer</i> , 2014, 50, 679-689.	2.8	40
43	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. , 1998, 83, 409-414.		37
44	Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7287-7293.	7.0	37
45	Challenges in Oncology. <i>Journal of Clinical Oncology</i> , 2002, 20, 870-872.	1.6	34
46	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. <i>Clinical Cancer Research</i> , 2015, 21, 3178-3186.	7.0	34
47	Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. <i>British Journal of Haematology</i> , 1994, 87, 153-161.	2.5	30
48	Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. <i>European Journal of Cancer</i> , 2014, 50, 981-986.	2.8	29
49	Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. <i>International Journal of Clinical Oncology</i> , 2015, 20, 905-912.	2.2	27
50	Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of <i>NTRK1</i> . <i>JCO Precision Oncology</i> , 2020, 4, 79-90.	3.0	27
51	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. <i>Oncologist</i> , 2015, 20, 823-830.	3.7	26
52	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2016, 61, 94-101.	2.8	25
53	Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. <i>Molecular Cancer Research</i> , 2020, 18, 1302-1314.	3.4	24
54	Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020. <i>Clinical Cancer Research</i> , 2022, 28, 27-35.	7.0	22

#	ARTICLE	IF	CITATIONS
55	First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3556-3566.	7.0	21
56	Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5746-E5755.	7.1	20
57	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. <i>BMC Cancer</i> , 2019, 19, 794.	2.6	20
58	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. <i>Cancer Discovery</i> , 2021, 11, 1508-1523.	9.4	20
59	Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers. <i>Future Oncology</i> , 2020, 16, 417-425.	2.4	19
60	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1695-1705.	7.0	19
61	LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications. <i>Cancers</i> , 2020, 12, 757.	3.7	18
62	Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. <i>Cancer Research</i> , 2019, 79, 994-1009.	0.9	17
63	A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. <i>European Journal of Cancer</i> , 2020, 126, 21-32.	2.8	16
64	Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 5135-5142.	7.0	14
65	HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2021, 27, 1706-1719.	7.0	14
66	Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. , 1999, 86, 1621-1627.		13
67	ET-743: the US experience in sarcomas of soft tissues. <i>Anti-Cancer Drugs</i> , 2002, 13 Suppl 1, S7-9.	1.4	12
68	Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. , 2019, 7, 296.		11
69	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. <i>Cancer</i> , 2019, 125, 4435-4441.	4.1	10
70	The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 29-39.	2.4	10
71	Case 32-2004. <i>New England Journal of Medicine</i> , 2004, 351, 1779-1787.	27.0	9
72	Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. <i>Cancer</i> , 1994, 74, 1887-1890.	4.1	8

#	ARTICLE	IF	CITATIONS
73	Evolution of the International Sarcoma Community: A Personal Perspective. <i>Oncology</i> , 2018, 95, 1-4.	1.9	7
74	Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial. <i>BMC Cancer</i> , 2018, 18, 790.	2.6	7
75	Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment. <i>Sarcoma</i> , 2015, 2015, 1-5.	1.3	6
76	Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 3565-3574.	2.8	6
77	Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. <i>Clinical Cancer Research</i> , 2022, 28, 2397-2408.	7.0	6
78	The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2399-2404.	2.4	5
79	FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs. <i>Clinical Cancer Research</i> , 2021, 27, 916-921.	7.0	4
80	Personalized Comments on Challenges and Opportunities in Kidney Disease Therapeutics: The Glom-NExT Symposium. <i>Seminars in Nephrology</i> , 2016, 36, 448.	1.6	2
81	Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors. <i>F1000Research</i> , 2013, 2, 152.	1.6	2
82	Derivation and validation of a risk classification tree for patients with synovial sarcoma. <i>Cancer Medicine</i> , 0, , .	2.8	2
83	Two Patients With Sarcoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2343-2344.	1.6	1
84	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. , 1998, 83, 409.		1
85	Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). , 0, .		1
86	Tales of Personalized Cancer Treatment. <i>Seminars in Nephrology</i> , 2016, 36, 462-467.	1.6	0
87	A Novel Role for CpG Oligonucleotides in Tumor Immunotherapy: CpG-ODN Induce Targeted Chemokine-Induced Lymphocyte Migration to the Peripheral Tissues in Humans.. <i>Blood</i> , 2007, 110, 1791-1791.	1.4	0
88	Clinical evidence from two phase 3 trials supporting statistical adjustment methods to assess confounding impact of treatment crossover on overall survival (OS).. <i>Journal of Clinical Oncology</i> , 2017, 35, e22509-e22509.	1.6	0
89	Disease state awareness in sarcoma. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 543-5.	0.3	0
90	Abstract 5648: Response and resistance to CDK2 and CDK4/6 inhibition in GIST. <i>Cancer Research</i> , 2022, 82, 5648-5648.	0.9	0